Clinical Trials
26 trialsNCT05399329 2026-04-09
Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan
Pfizer
Completed
NCT06962969 2026-04-02
A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database
Pfizer
Completed
NCT04671615 2025-12-10
A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.
Pfizer
Completed
NCT04735367 2025-12-09
Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole
Pfizer
Completed
NCT06086340 2025-11-18
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
Pfizer
Completed
NCT07096024 2025-08-28
A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market
Pfizer
Completed
NCT06307457 2025-06-29
A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.
Pfizer
Completed
NCT06525675 2024-12-13
Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)
MedSIR
Completed
NCT05012644 2024-10-08
Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone
Pfizer
Completed
NCT06607601 2024-09-23
CARE Initiative: Real-world Emulation of the PALOMA-2 Trial
Aetion, Inc.
Completed
NCT04176354 2024-08-23
Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy
Pfizer
Completed
NCT05361655 2024-06-07
Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor
Pfizer
Completed
NCT06003114 2024-05-16
A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs
Pfizer
Completed
NCT06367335 2024-04-16
ETIC
University of Milano Bicocca
Completed
NCT05043506 2024-03-27
EUCHARIS
Pfizer
Completed
NCT05584644 2023-12-19
A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer
Pfizer
Completed
NCT04916509 2023-06-06
Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region
Pfizer
Completed
NCT02154490 2023-06-01
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network
Completed
NCT03285568 2023-03-31
Patterns of Prescribing and Monitoring of Palbociclib
Rush University Medical Center
Completed
NCT03921866 2023-03-17
ROIS
Pfizer
Completed
NCT04874025 2022-08-08
PALBOSPAIN
Hospital San Carlos, Madrid
Completed
NCT04992156 2022-05-19
Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET
Fudan University
Completed
NCT05153135 2021-12-21
Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors
Novartis
Completed
NCT05141240 2021-12-16
A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors
Novartis
Completed
NCT04524728 2020-08-24
Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy
Istituti Clinici Scientifici Maugeri SpA
Completed
NCT04109261 2019-09-30
PALBOCOMP
Hospital San Carlos, Madrid
Completed